225 related articles for article (PubMed ID: 30250538)
1. A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA.
Wei L; Wu W; Han L; Yu W; Du Y
Oncol Lett; 2018 Oct; 16(4):4353-4360. PubMed ID: 30250538
[TBL] [Abstract][Full Text] [Related]
2. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
[TBL] [Abstract][Full Text] [Related]
4. Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer.
Chen J; Shao J; Zhang X; Wei S; Cai H; Wang G
Ann Transl Med; 2022 Mar; 10(5):253. PubMed ID: 35402598
[TBL] [Abstract][Full Text] [Related]
5. Analysis of serum cfDNA concentration and integrity before and after surgery in patients with lung cancer.
Fan Y; Shi M; Chen S; Ju G; Chen L; Lu H; Chen J; Zheng S
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):56-63. PubMed ID: 31472048
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.
Kapeleris J; Müller Bark J; Ranjit S; Irwin D; Hartel G; Warkiani ME; Leo P; O'Leary C; Ladwa R; O'Byrne K; Hughes BGM; Punyadeera C
Heliyon; 2022 Jul; 8(7):e09971. PubMed ID: 35874074
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
González de Aledo-Castillo JM; Arcocha A; Victoria I; Martinez-Puchol AI; Sánchez C; Jares P; Rodríguez GF; Viñolas N; Reyes R; Reguart N; Puig-Butillé JA
J Thorac Dis; 2021 Mar; 13(3):1658-1670. PubMed ID: 33841957
[TBL] [Abstract][Full Text] [Related]
10.
Garzón M; Villatoro S; Teixidó C; Mayo C; Martínez A; de Los Llanos Gil M; Viteri S; Morales-Espinosa D; Rosell R
Transl Lung Cancer Res; 2016 Oct; 5(5):511-516. PubMed ID: 27826532
[TBL] [Abstract][Full Text] [Related]
11. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
12. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
13. Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study.
Wang X; Zhi X; Zhang Y; An G; Feng G
J Thorac Dis; 2016 Jul; 8(7):1645-52. PubMed ID: 27499953
[TBL] [Abstract][Full Text] [Related]
14. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.
He X; Chi Y; Peng J; Hu W; Ding C; Li B
J Thorac Dis; 2022 Jun; 14(6):2103-2111. PubMed ID: 35813759
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
Hyun MH; Lee ES; Eo JS; Kim S; Kang EJ; Sung JS; Choi YJ; Park KH; Shin SW; Lee SY; Kim YH
Lung Cancer; 2019 Aug; 134():158-166. PubMed ID: 31319975
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer.
Sharma SK; Bhat S; Chandel V; Sharma M; Sharma P; Gupta S; Sharma S; Bhat AA
J Carcinog; 2015; 14():7. PubMed ID: 26900349
[TBL] [Abstract][Full Text] [Related]
18. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
19. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer.
Shang L; Zhang W; Wu H; Wu R; Chen R
Evid Based Complement Alternat Med; 2021; 2021():1436088. PubMed ID: 34691202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
